natgillin/translations-raw huggingface dataset:
Tell your doctor, pharmacist or nurse immediately if you notice any symptoms of infection or other symptoms such as: muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity.
Nemudoma obvestite zdravnika, farmacevta ali medicinsko sestro, če opazite kateri koli simptom okužbe ali kateri koli drug simptom, na primer: šibkost mišic, šibkost, ki se začne v dlaneh in stopalih in se širi navzgor proti trupu, razbijanje srca (palpitacije), tresenje ali hiperaktivnost.
Tell your doctor, pharmacist or nurse immediately if you notice any symptoms of infection, such as: fever, and/or feeling unwell.
Nemudoma obvestite zdravnika, farmacevta ali medicinsko sestro, če opazite kateri koli simptom okužbe, na primer: zvišano telesno temperaturo in/ali slabo počutje.
Tell your doctor, pharmacist or nurse straight away if you notice any of the following serious side effects – you may need urgent medical treatment:
Če opazite katerega koli od naslednjih resnih neželenih učinkov, se takoj posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, kajti morda boste potrebovali nujno medicinsko pomoč:
Tell your doctor, pharmacist, or nurse if you are planning on receiving a vaccine or a medicine that suppresses the immune system, as you may need to be closely monitored.
Obvestite zdravnika, farmacevta ali medicinsko sestro, če imate predvideno kakšno cepljenje ali uporabo zdravila, ki zavira imunski sistem, ker boste morda potrebovali skrbno spremljanje.
Tell your doctor, you may need to stop taking Moventig.
O tem obvestite zdravnika, morda boste morali nehati jemati zdravilo Moventig.
Tell your doctor.
e posvetujte s svojim zdravnikom.
Tell your doctor.
e posvetujte z zdravnikom.
Tell your doctor.
Obvestite svojega zdravnika.
Tell your doctor...
Obvestite zdravnika,
Tell your doctor:
Obvestite svojega zdravnika, če:
Tell your doctor:
Svojemu zdravniku povejte:
Tell your health care provider about any other medicines you are currently taking, took recently or intend to start taking, before you start Xarelto.
Pred začetkom zdravljenja z zdravilom Xarelto obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Tell your health care provider straight away if you have any signs or symptoms of bleeding such as the following:
Takoj obvestite zdravnika, če imate znake ali simptome krvavitve, kot so:
Tell your health care provider that you are taking Xarelto before any surgery or invasive procedure.
Pred katerim koli kirurškim posegom ali invazivnim postopkom obvestite zdravnika, da jemljete zdravilo Xarelto.
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the images obtained from the brain scan.
Obvestite svojega zdravnika nuklearne medicine, če jemljete ali ste pred kratkim jemali katera koli druga zdravila, saj lahko vplivajo na interpretacijo slik, ki jih dobimo po slikanju možganov.
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images.
Obvestite svojega zdravnika nuklearne medicine, če jemljete, ste pred kratkim jemali ali boste morda začeli jemati katero koli drugo zdravilo, saj lahko ovirajo tolmačenje posnetkov.
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images.
Obvestite zdravnika nuklearne medicine, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo, saj bi ta lahko motila interpretacijo slik.
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images.
Obvestite zdravnika nuklearne medicine, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo, saj bi ta lahko motila razlago slik.
Tell your pharmacist if you notice any change in the appearance of the tablets.
Če opazite kakšno spremembo videza tablet, morate to povedati farmacevtu.
Tell your pharmacist, doctor or other healthcare professional if you are taking, have recently taken or might take any other medicines.
Obvestite farmacevta, zdravnika ali drugega zdravstvenega delavca, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Tell your relatives, friends and close colleagues that if you pass out (become unconscious), they must: turn you on your side and seek medical advice straight away.
Svojim sorodnikom, prijateljem in bližnjim sodelavcem povejte, da vas morajo v primeru, da se onesvestite (izgubite zavest), položiti na bok in nemudoma poiskati zdravniško pomoc.
Tell your surgeon or dentist performing the procedure that you are having treatment with Cimzia by showing them your Patient Alert Card.
Kirurgu ali zobozdravniku, ki bo poseg opravljal, povejte, da se zdravite z zdravilom Cimzia in mu pokažite Opozorilno kartico za bolnika.
Tell your surgeon or dentist performing the procedure that you are having treatment with Flixabi by showing them your Patient Alert Card.
Obvestite kirurga ali zobozdravnika, da prejemate zdravilo Flixabi, in mu pokažite opozorilno kartico bolnika.
Tell your surgeon or dentist performing the procedure that you are having treatment with Inflectra by showing them your Patient Alert Card.
Obvestite svojega kirurga ali zobozdravnika, da prejemate zdravilo Inflectra in mu pokažite opozorilno kartico bolnika.
Tell your surgeon or dentist performing the procedure that you are having treatment with Remicade by showing them your Patient Alert Card.
Obvestite kirurga ali zobozdravnika, da prejemate zdravilo Remicade in mu pokažite opozorilno kartico bolnika.
Tell your surgeon or dentist performing the procedure that you are having treatment with Remsima by showing them your Patient Alert Card.
Obvestite kirurga ali zobozdravnika, da prejemate zdravilo Remsima in mu pokažite opozorilno kartico bolnika.
Tell your surgeon or dentist performing the procedure that you are having treatment with Simponi by showing them your Patient Alert Card.
Kirurgu ali zobozdravniku, ki bo opravil poseg, povejte, da se zdravite z zdravilom Simponi, in mu pokažite bolnikovo opozorilno kartico.
Tell your veterinarian about all medicines, including over- the-counter products, that you intend to administer to your dog.
Vašemu veterinarju povejte o vseh zdravilih, vključno z zdravili brez recepta, ki jih nameravate dati vašemu psu.
Tell your veterinary surgeon if you notice any of the following: significant loss of appetite.
Če opazite katerega od spodnjih neželenih učinkov, obvestite svojega veterinarja: izrazita izguba teka.
Telmisartan
Telmisartan Actavis
Telmisartan Actavis blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.
Zdravilo Telmisartan Actavis blokira učinek angiotenzina II; žile se sprostijo in krvni tlak se zniža.
Telmisartan Actavis contains the active substance telmisartan which belongs to a class of medicines known as angiotensin II receptor antagonists.
Zdravilo Telmisartan Actavis vsebuje zdravilno učinkovino telmisartan, ki spada v skupino zdravil, imenovanih antagonisti receptorjev angiotenzina II.
Telmisartan Actavis is a ‘generic medicine’.
Zdravilo Telmisartan Actavis je „generično zdravilo“.
Telmisartan Actavis is contraindicated in patients with severe hepatic impairment (see section 4.3).
Zdravilo Telmisartan Actavis je kontraindicirano pri bolnikih s hudo jetrno okvaro (glejte poglavje 4.3).
Telmisartan Actavis is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.
Zdravila Telmisartan Actavis ne smejo dobiti bolniki s holestazo, biliarnimi obstruktivnimi motnjami ali hudo okvaro jeter (glejte poglavje 4.3), ker se telmisartan v glavnem izloča z žolčem.
Telmisartan Actavis may also be used in combination with diuretics (‘water tablets’) such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with telmisartan.
Telmisartan se lahko uporablja tudi v kombinaciji z diuretiki (tablete za odvajanje vode), kot je hidroklorotiazid; dokazano je, da je tako dosežen aditiven učinek na znižanje krvnega tlaka s telmisartanom.
Telmisartan Actavis may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine).
Zdravilo Telmisartan Actavis lahko poveča znižanje krvnega tlaka, ki ga povzročijo druga zdravila za zdravljenje visokega krvnega tlaka, ali zdravil z možnim antihipertenzivnim učinkom (npr. baklofen, amifostin).
Telmisartan and amlodipine are not dialysable.
Telmisartan in amlodipin se med hemodializo ne odstranita.
Telmisartan and Amlodipine are not removed by haemodialysis.
Amlodipin in telmisartan se med hemodializo ne odstranita.
Telmisartan belongs to a group of substances called “angiotensin-II receptor antagonists”.
Telmisartan sodi v skupino učinkovin, ki jih imenujemo 'antagonisti receptorjev za angiotenzin II'.
Telmisartan changes MPA’s elimination by enhancing PPAR gamma (peroxisome proliferator-activated receptor gamma) expression, which in turn results in an enhanced UGT1A9 expression and activity.
Telmisartan spreminja izločanje mikofenolne kisline tako, da okrepi izražanje receptorja PPAR gama (peroxisome proliferator-activated receptor gamma), kar posledično okrepi izražanje in aktivnost encima UGT1A9.
Telmisartan displaces angiotensin II from its binding site at the AT1 receptor subtype.
Telmisartan izpodrine angiotenzin II z njegovih vezavnih mest na podvrsti receptorjev AT1.
Telmisartan does not exhibit any partial agonist activity at the type AT1 receptor.
Telmisartan nima delnega agonističnega učinka na receptorjih AT1.
Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist which causes a dose dependent decrease in mean arterial blood pressure in mammalian species including the cat.
Telmisartan je peroralno aktiven specifičen antagonist receptorja angiotenzina II (tip AT1), ki povzroči od odmerka odvisno znižanje povprečnega arterijskega krvnega tlaka pri vrstah sesalcev, vključno z mačkami.
Telmisartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Telmisartan je antagonist receptorjev angiotenzina II, kar pomeni, da v telesu prepreči delovanje hormona, imenovanega angiotenzin II.
Telmisartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Telmisartan je antagonist receptorjev angiotenzina II, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half- life of >20 hours.
Za telmisartan je značilna farmakokinetika dvoeksponentne razgradnje s končno razpolovno dobo izločanja > 20 ur.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of
Za telmisartan je značilna farmakokinetika dvoeksponentne razgradnje s končno razpolovno dobo izločanja
Telmisartan is highly bound to plasma proteins (>99.5 %) mainly albumin and alpha l-acid glycoprotein.
Telmisartan se obsežno veže na plazemske beljakovine (> 99,5°%), predvsem albumin in kisli glikoprotein alfa-1.
Telmisartan is highly lipophilic and has rapid membrane permeability kinetics, which facilitates easy distribution into tissue.
Telmisartan je izjemno lipofilen in ima hitro kinetiko membranske prepustnosti, kar olajša porazdelitev v tkivu.
Telmisartan is largely bound to plasma protein (> 99.5%), mainly albumin and alpha-1 acid glycoprotein.
Telmisartan je v veliki meri vezan na beljakovine v plazmi (> 99,5 %), predvsem albumin in alfa-1 kisli glikoprotein.
Telmisartan is largely bound to plasma protein (>99.5 %), mainly albumin and alpha-1 acid glycoprotein.
Telmisartan se obsežno veže na plazemske beljakovine (>99,5 %), predvsem albumin in kisli glikoprotein alfa-1.
Telmisartan is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Uporaba zdravila Telmisartan Actavis ni priporočljiva v zgodnjem obdobju nosečnosti in ga ne smete jemati, če ste noseči več kot 3 mesece, ker lahko v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti).
Telmisartan is not removed from blood by haemodialysis.
Telmisartan se s hemodializo ne izloča iz telesa.
Telmisartan selectively binds the AT1 receptor.
Nanj se veže selektivno.
Telmisartan should be kept in the sealed blister due to the hygroscopic property of the tablets.
Zdravilo Micardis je treba shranjevati v zaprtem pretisnem omotu, ker so tablete higroskopične.
Telmisartan tablets are for once-daily oral administration and should be taken with liquid, with or without food.
Telmisartan Teva Pharma tablete se jemljejo peroralno enkrat na dan s tekočino, s hrano ali brez nje.
Telmisartan Teva
Telmisartan
Telmisartan Teva is a ‘generic medicine’.
Telmisartan Teva je „generično zdravilo“.
Telmisartan Teva Pharma 20 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93".
Telmisartan Teva Pharma 20 mg tablete so bele do belkaste, ovalne tablete.
Telmisartan Teva Pharma 40 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93".
Telmisartan Teva Pharma 40 mg tablete so bele do belkaste, ovalne tablete.
Telmisartan Teva Pharma 80 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93".
Telmisartan Teva Pharma 80 mg tablete so bele do belkaste, ovalne tablete.
Telmisartan Teva Pharma is a ‘generic medicine’.
Telmisartan Teva Pharma je „generično zdravilo“.
Telmisartan Teva Pharma is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes.
Zdravilo Telmisartan Teva Pharma uporabljamo tudi za zmanjševanje srčnožilnih dogodkov (npr. srčnega napada ali možganske kapi) pri odraslih z velikim tveganjem zaradi zmanjšane ali blokirane oskrbe srca ali nog s krvjo, ali pri odraslih, ki so doživeli možgansko kap ali imajo sladkorno bolezen z velikim tveganjem.
Telmisartan Teva Pharma is contraindicated in patients with severe hepatic impairment (see section 4.3).
Zdravilo Telmisartan Teva Pharma je kontraindicirano pri bolnikih s hudo jetrno okvaro (glejte poglavje 4.3).
Telmisartan Teva Pharma is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Telmisartan Teva Pharma ni priporočljiva v zgodnjem obdobju nosečnosti in ga ne smete jemati, če ste noseči več kot 3 mesece, ker lahko v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti in dojenju).
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.90 - 1.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Telmisartan je učinkoval podobno kot ramipril na vnaprej opredeljeni sekundarni opazovani dogodek, ki je zajemal srčnožilno smrt, neusodni miokardni infarkt in neusodno možgansko kap [0,99 (97,5- odstotni IZ 0,90 do 1,08), p (enakovrednost) = 0,0004], in je bil primarni opazovani dogodek v referenčni raziskavi HOPE (The Heart Outcome Prevention Evaluation Study), v kateri so ramipril primerjali s placebom.
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.90 - 1.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Telmisartan je učinkoval podobno kot ramipril na vnaprej opredeljeni sekundarni opazovani dogodek, ki je zajemal srčnožilno smrt, neusodni miokardni infarkt in neusodno možgansko kap [0,99 (97,5-odstotni IZ 0,90 do 1,08), p (enakovrednost) = 0,0004], in je bil primarni opazovani dogodek v referenčni raziskavi HOPE (The Heart Outcome Prevention Evaluation Study), v kateri so ramipril primerjali s placebom.
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5% CI 0.90 - 1.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Ugotovili so, da je telmisartan podobno učinkovit kot ramipril glede vnaprej opredeljenega sekundarnega opazovanega dogodka srčnožilne smrti, miokardnega infarkta brez smrtnega izida in možganske kapi brez smrtnega izida [0,99 (97, 5 % IZ 0,90–1,08), p (neinferiornost) = 0,0004], kar je bil primarni opazovani dogodek v referenčni študiji HOPE (The Heart Outcomes Prevention Evaluation Study), ki je proučevala učinek ramiprila v primerjavi s placebom.
Telmisartan:
Telmisartan
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Po intravenskem ali peroralnem dajanju s 14C označenega telmisartana se je večina odmerka (> 97 %) izločila z blatom po biliarni poti.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Po intravenskem ali peroralnem dajanju s C14 označenega telmisartana se je večina odmerka (> 97 %) izločila z blatom po biliarni poti.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Po intravenskem ali peroralnem dajanju s C14 označenega telmisartana se je večina odmerka (> 97°%) izločila z blatom po biliarni poti.
Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 – 1.5 h after dosing.
Telmisartan: Telmisartan doseže po peroralnem dajanju največjo koncentracijo v 0,5 do 1,5 ure.
Telmisartan: Following oral administration, peak concentrations of telmisartan are reached in 0.5-1.5 h after dosing.
Telmisartan: Telmisartan doseže po peroralnem dajanju največjo koncentracijo v 0,5 do 1,5°ure.
Telzir 700 mg film-coated tablets
Telzir 700 mg filmsko obložene tablete
Telzir 700 mg film-coated tablets
Telzir 700 mg filmsko obložene tablete fosamprenavir
Telzir can make you feel dizzy and have other side effects that make you less alert.
Zdravilo Telzir lahko povzroči omotico in druge neželene učinke, ki lahko zmanjšajo zbranost.
Telzir does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Telzir ne zdravi okužbe z virusom HIV ali aidsa, lahko pa podaljša čas do pojava okvar imunskega sistema ter razvoja okužb in bolezni, povezanih z aidsom.
Telzir has been studied in three main studies involving 1,862 adults infected with HIV.
Zdravilo Telzir so proučevali v treh glavnih študijah, ki so vključevale 1 862 odraslih, okuženih z virusom HIV.
Telzir in combination with low dose ritonavir is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products.
Zdravilo Telzir je v kombinaciji z nizkim odmerkom ritonavirja in v kombinaciji z drugimi protiretrovirusnimi zdravili indicirano za zdravljenje odraslih, mladostnikov in otrok, starejših od 6 let, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1).
Telzir is a medicine that contains the active substance fosamprenavir.
Telzir je zdravilo, ki vsebuje zdravilno učinkovino fosamprenavir.
Telzir is also available as a liquid (oral suspension) for people who are unable to swallow tablets. (Read the package leaflet of Telzir oral suspension for guidance on whether to take it with or without food.)
Zdravilo Telzir je na voljo tudi v obliki tekočine (peroralna suspenzija), ki je namenjena bolnikom, ki ne morejo pogoltniti tablet. (Za navodila za uporabo Telzir peroralne suspenzije skupaj s hrano ali brez nje glejte navodila za uporabo Telzir peroralne suspenzije.)
Telzir is also available as an oral suspension for those patients unable to swallow the tablets.
Za bolnike, ki ne morejo pogoltniti tablet, je zdravilo Telzir na voljo tudi v obliki peroralne suspenzije.
Telzir is not recommended for children less than 6 years old.
Zdravilo Telzir ni priporočljivo za otroke, mlajše od 6 let.
Telzir is supplied in plastic bottles containing 60 film-coated tablets.
Zdravilo Telzir je na voljo v plastenkah, ki vsebujejo 60 filmsko obloženih tablet.
Telzir is used in combination with ritonavir and other antiviral medicines to treat patients aged six years or above who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Telzir se uporablja v kombinaciji z ritonavirjem in drugimi protivirusnimi zdravili za zdravljenje bolnikov, starejših od šestih let, ki so okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV- 1), ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Telzir may require dose reduction (using oral
Morda bo potrebno zmanjšati odmerek zdravila Telzir (z uporabo peroralne suspenzije).
Telzir must not be used in patients who are taking rifampicin (used to treat tuberculosis), St John’s wort (a herbal preparation used to treat depression), or medicines that are broken down in the same way as Telzir or ritonavir and are harmful at high levels in the blood.
Zdravilo Telzir se prav tako ne sme uporabljati pri bolnikih, ki jemljejo rifampicin (zdravilo za zdravljenje tuberkuloze), šentjanževko (rastlinski pripravek za zdravljenje depresije) ali zdravila, ki se presnavljajo na enak način kot zdravilo Telzir ali ritonavir in katerih visoke ravni v krvi so škodljive.
Telzir oral suspension contains propyl and methyl parahydroxybenzoate.
Zdravilo Telzir peroralna suspenzija vsebuje propilparahidroksibenzoat in metilparahidroksibenzoat.
Telzir should not be used in people who may be hypersensitive (allergic) to fosamprenavir, amprenavir, any of the other ingredients, or ritonavir.
Zdravilo Telzir se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) fosamprenavir, amprenavir ali katero koli drugo sestavino zdravila ali ritonavir.
Telzir tablet and oral suspension formulations, both given fasted, delivered equivalent plasma amprenavir AUC values and the Telzir oral suspension formulation delivered a 14 % higher plasma amprenavir Cmax as compared to the oral tablet formulation.
Po dajanju zdravila Telzir na tešče, bodisi tablet bodisi peroralne suspenzije, so si vrednosti AUC amprenavirja v plazmi enakovredne, v primerjavi z dajanjem zdravila Telzir v obliki tablet pa je po dajanju peroralne suspenzije Cmax amprenavirja v plazmi za 14 % večja.